Cary Street Partners Investment Advisory’s Haemonetics HAE Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$225	Sell	3 -3	-50%	-$193	﹤0.01%	756
2026 Q1	$338	Buy	6 +5	+500%	+$326	﹤0.01%	689
2025 Q4	$80	Sell	1 -2	-67%	-$134	﹤0.01%	680
2025 Q3	$146	Sell	3 -10	-77%	-$619	﹤0.01%	609
2025 Q2	$970	Sell	13 -4	-24%	-$265	﹤0.01%	581
2025 Q1	$1.08K	Buy	+17	New	+$1.16K	﹤0.01%	550

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cary Street Partners Investment Advisory's HAE Position: Q2 2026 in Review

Cary Street Partners Investment Advisory reduced its Haemonetics (HAE) stake by 50% in Q2 2026, selling an estimated $193 and leaving 3 shares worth $225. The position accounts for ﹤0.01% of the portfolio, ranked #756.

Cary Street Partners Investment Advisory first reported a position in HAE in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.08K in Q1 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Cary Street Partners Investment Advisory held 3 shares of Haemonetics worth $225 as of Q2 2026.
Cary Street Partners Investment Advisory sold 3 Haemonetics shares in Q2 2026, an estimated $193.
Haemonetics made up ﹤0.01% of Cary Street Partners Investment Advisory's portfolio in Q2 2026, its #756 holding.
Cary Street Partners Investment Advisory first reported a position in Haemonetics in Q1 2025 and has held it in 6 quarters since.
Cary Street Partners Investment Advisory's Haemonetics position peaked at $1.08K in Q1 2025.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Cary Street Partners Investment Advisory's 13F filing for Q2 2026, filed 17 Jul 2026.